Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
Date:3/26/2009

SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview on Thursday, April 2, 2009 at 9:00am Eastern Time (6:00am Pacific Time) during the BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:  William R. LaRue
               SVP, CFO
               Cadence Pharmaceuticals, Inc.
               858-436-1400


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Custom Learning Designs, Inc.(CLD) ... solution using Tin Can API combined with its ... is a leading developer of training content and ... worldwide. , Tin Can API is a ... and trainers more accurately measure the Return on ...
(Date:5/21/2013)... May 21, 2013 The congress ... Transplant Association) is the biggest congress in ... Nearly 10,000 participants are in Istanbul ... research findings. New pioneering studies have been presented: ... PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" ...
(Date:5/21/2013)... York , May 21, 2013 ... Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and ... IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and ... billion in 2011 and is expected to grow at ... reach an estimated value of USD 4.7 billion in ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... Jan. 11 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... and,commercial development of technologies targeting the chronic inflammation,underlying ... at 4:10 p.m. on Wednesday, January 16, 2008. ... Time, during which management will,provide a Company update ...
... by Mark Walton, Ph.D., President, ViaGen, January 11, ... the,European Food Safety Authority,s strong endorsement of the safety ... U.S. Food and Drug,Administration to release its final risk ... voluntary moratorium. The international,scientific consensus is clear: food from ...
... Biodesign Institute have developed the worlds first gene detection ... results, appearing in the January 11 issue of the ... technology and may also revolutionize the way in which ... We are starting with the most well-known structure in ...
Cached Biology Technology:Vasogen to Conduct Year-end 2007 Conference Call 2Vasogen to Conduct Year-end 2007 Conference Call 3Vasogen to Conduct Year-end 2007 Conference Call 4Statement on the Release of the European Food Safety Assessment on the Safety of Food Derived From Clones and Their Offspring in the Food Supply 2Nanotechnology innovation may revolutionize gene detection in a single cell 2Nanotechnology innovation may revolutionize gene detection in a single cell 3
(Date:5/21/2013)... shape is an uphill battle? Try staying fit in ... withers muscle and bone. , That,s the challenge a ... a new three-year, $1.2 million grant from NASA. Their ... multiyear exploratory missions. , "You could give astronauts the ... get them to stick to it, it isn,t going ...
(Date:5/21/2013)... of insulin action in cells in precise detail like ... what goes wrong in diabetes. , The breakthrough ... from Sydney,s Garvan Institute of Medical Research, is now ... journal Cell Metabolism . , First discovered in ... in the body because it helps us lower blood ...
(Date:5/20/2013)... University of Minnesota Medical School researchers from the ... the University,s Brain Tumor Program, have developed a new ... that allow them to discover new genes and gene ... was published this week in the journal Nature ... researchers in the lab of David Largaespada, Ph.D., professor ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2
... The history of evolution is periodically marked by explosions ... wide range of shapes and sizes. With a new ... record, researchers have discovered that these diversifications proceeded head-first. ... that diversified around the time of two separate extinction ...
... to help prevent or reduce severe wildfire will release more ... fire prevention, a new study concludes. There may be ... forest structure or health, wildlife enhancement or public safety ... say. In research just published in Frontiers in ...
... LIFE the Faculty of Life Sciences at the University ... growth pattern than non-breastfed children. Breastfeeding lowers the levels of ... means that growth is slightly slower. This is believed to ... The PhD project is part of SKOT, a ...
Cached Biology News:'Head-first' diversity shown to drive vertebrate evolution 2'Head-first' diversity shown to drive vertebrate evolution 3Forest health versus global warming: Fuel reduction likely to increase carbon emissions 2Breastfeeding promotes healthy growth 2
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
... System is used in conjunction ... PCR of problematic and/or GC-rich ... Solution with 10X PCRX Amplification ... broader magnesium concentration broader annealing ...
Biology Products: